The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production.
OBJECTIVE
This study was aimed at investigating the involvement of an altered cytokine pattern in the immunomodulatory and anti-abortive effects of a progesterone-induced immunomodulatory protein (PIBF).


METHODS
PIBF expression on lymphocytes of healthy pregnant women and from women at risk for premature pregnancy termination was determined. In sera of the same women TNF alpha was quantified by a bioassay using L929 cells. NK activity was determined by a single cell cytotoxicity assay. Cytokine production of the lymphocytes or murine spleen cells was measured by ELISA or detected by immunocytochemistry. In pregnant mice endogenous PIBF activity was neutralized by anti-PIBF IgG.


RESULTS
Sera of women at risk for premature pregnancy termination contained significantly higher concentrations of TNF alpha than those from healthy pregnant women and PIBF expression on the lymphocytes was inversely related to serum concentration of TNF alpha. Increased NK activity of lymphocytes after neutralization of endogenous PIBF activity is corrected by anti-IL 2 treatment and PIBF inhibits IL 12 expression on activated lymphocytes. PIBF increases IL-10 production by activated spleen cells. In pregnant mice, neutralization of endogenous PIBF activity by specific antibody results in increased resorption rate and reduced splenic IL-10 production.


CONCLUSIONS
Our data allow the assumption that via blocking IL-12 production PIBF inhibits NK activation with a concomitant reduction of TNF alpha levels. Disturbances in this system might lead to the expression of the known synergistic effect of IL-12 and TNF alpha, resulting in a Th 1 type cytokine dominance and pregnancy termination.
Szekeres-Bartho
J
J
Department of Microbiology, University Medical School of Pecs, Hungary.
Faust
Z
Z
Varga
P
P
Szereday
L
L
Kelemen
K
K
D000022:Abortion, Spontaneous / Q000276:immunology / Q000517:prevention & control*; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis* / Q000187:drug effects; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis; D018664:Interleukin-12 / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000187:drug effects / Q000378:metabolism*; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000276:immunology / Q000494:pharmacology*; D011374:Progesterone / Q000276:immunology / Q000494:pharmacology*; D013491:Suppressor Factors, Immunologic; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000187:drug effects
D000276:Adjuvants, Immunologic; D016207:Cytokines; C110058:PIBF1 protein, human; D011257:Pregnancy Proteins; D013491:Suppressor Factors, Immunologic; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D018664:Interleukin-12; D011374:Progesterone